当前位置: 首页 » 政策法规 » 国外法规 »(EU) No 677/2014:就卡麦角林(cabergoline),修订法规(EU) No 37/2010(amending Regulation (EU) No 37/2010, as regards the substance ‘cabergoline’)

(EU) No 677/2014:就卡麦角林(cabergoline),修订法规(EU) No 37/2010(amending Regulation (EU) No 37/2010, as regards the substance ‘cabergoline’)

扫描二维码 分享好友和朋友圈
放大字体  缩小字体 2014-06-20 04:19:35  来源:EUROPE  浏览次数:3531
核心提示:2014年6月20日,欧盟发布委员会实施条例(EU) No 677/2014,设立药理学活性物质卡麦角林(Cabergoline)在牛的脂肪、肝脏、肾脏、肌肉和牛乳中的最大残留限量,分别为0,10 μg/kg,0,25 μg/kg,0,50 μg/kg,0,15 μg/kg和0,10 μg/kg。
发布单位
EUROPEAN COMMISSION
EUROPEAN COMMISSION
发布文号 (EU) No 677/2014
发布日期 2014-06-20 生效日期 暂无
有效性状态 废止日期 暂无
备注 2014年6月20日,欧盟发布委员会实施条例(EU) No 677/2014,设立药理学活性物质卡麦角林(Cabergoline)在牛的脂肪、肝脏、肾脏、肌肉和牛乳中的最大残留限量,分别为0,10 μg/kg,0,25 μg/kg,0,50 μg/kg,0,15 μg/kg和0,10 μg/kg。

  COMMISSION IMPLEMENTING REGULATION (EU) No 677/2014

  of 19 June 2014

  amending Regulation (EU) No 37/2010, as regards the substance ‘cabergoline’

  (Text with EEA relevance)

  THE EUROPEAN COMMISSION,

  Having regard to the Treaty on the Functioning of the European Union,

  Having regard to Regulation (EC) No 470/2009 of the European Parliament and of the Council of 6 May 2009 laying down Community procedures for the establishment of residue limits of pharmacologically active substances in foodstuffs of animal origin, repealing Council Regulation (EEC) No 2377/90 and amending Directive 2001/82/EC of the European Parliament and of the Council and Regulation (EC) No 726/2004 of the European Parliament and the Council (1), and in particular Article 14 in conjunction with Article 17 thereof,

  Having regard to the opinion of the European Medicines Agency formulated by the Committee for Medicinal Products for Veterinary Use,

  Whereas:

  (1)

  The maximum residue limit (hereinafter ‘MRL’) for pharmacologically active substances intended for use in the Union in veterinary medicinal products for food-producing animals or in biocidal products used in animal husbandry is to be established in accordance with Regulation (EC) No 470/2009.

  (2)

  Pharmacologically active substances and their classification regarding MRLs in foodstuffs of animal origin are set out in the Annex to Commission Regulation (EU) No 37/2010 (2).

  (3)

  An application for the establishment of maximum residue limits for cabergoline in bovine species has been submitted to the European Medicines Agency.

  (4)

  The Committee for Medicinal Products for Veterinary Use recommended the establishment of a MRL for cabergoline for bovine species, applicable to fat, liver, kidney, muscle and milk.

  (5)

  In accordance with Article 5 of Regulation (EC) No 470/2009 the European Medicines Agency is to consider using MRLs established for a pharmacologically active substance in a particular foodstuff for another foodstuff derived from the same species, or MRLs established for a pharmacologically active substance in one or more species for other species.

  (6)

  The Committee for Medicinal Products for Veterinary Use concluded that the extrapolation to other food producing species cannot be supported for this substance.

  (7)

  Regulation (EU) No 37/2010 should therefore be amended to include the substance cabergoline for bovine species.

  (8)

  It is appropriate to provide for a reasonable period of time for the stakeholders concerned to take measures that may be required to comply with the newly set MRL.

  (9)

  The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Veterinary Medicinal Products,

  HAS ADOPTED THIS REGULATION:

  Article 1

  The Annex to Regulation (EU) No 37/2010 is amended as set out in the Annex to this Regulation.

  Article 2

  This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.

  It shall apply from 18 August 2014.

  This Regulation shall be binding in its entirety and directly applicable in all Member States.

  Done at Brussels, 19 June 2014.

  For the Commission

  The President

  José Manuel BARROSO
 

ANNEX

In Table 1 of the Annex to Regulation (EU) No 37/2010, an entry for the following substance is inserted in alphabetical order:

Pharmacologically active Substance

Marker residue

Animal Species

MRL

Target Tissues

Other Provisions (according to Article 14(7) of Regulation (EC) No 470/2009)

Therapeutic Classification

‘Cabergoline

Cabergoline

Bovine

0,10 μg/kg

Fat

NO ENTRY

Prolactin inhibitor’

0,25 μg/kg

Liver

0,50 μg/kg

Kidney

0,15 μg/kg

Muscle

0,10 μg/kg

Milk


 

食品伙伴网提供标准法规解读、舆情监控、合规咨询、申报注册等服务。
电询:0535-2129301
QQ:2891238009
食品标法圈
实时把握食品标法动态
请扫码关注食品标法圈

声明:

① 凡本网所有原始/编译文章及图片、图表的版权均属食品伙伴网所有,如要转载,需注明“信息来源:食品伙伴网”。
② 凡本网注明“信息来源:XXX(非食品伙伴网)”的作品,均转载自其他媒体,转载目的在于传递更多的信息,并不代表本网赞同其观点和对其真实性负责。
※ 邮箱:law#foodmate.net(发邮件时请将#换成@) QQ:139307733

 
 
[ 政策法规搜索 ]  [ 加入收藏 ]  [ 告诉好友 ]  [ 打印本文 ]  [ 关闭窗口 ]

 

 
 
按分类浏览
国家法规 (11358) 国外法规 (3603)
地方法规 (39742) 法规动态 (210)
法规解读 (2623) 其他法规 (506)
推荐国外法规
点击排行
按国家或地区浏览

法规中心  关于我们  广告业务  联系我们  信息服务

Processed in 0.176 second(s), 10 queries, Memory 4.47 M